In the past decade, nucleic acid therapies have seen a boon in development and clinical
translation largely due to advances in nanotechnology that have enabled their safe and …

Despite impressive recent establishment of therapeutic nucleic acids as drugs and vaccines,
their broader medical use is impaired by modest performance in intracellular delivery …

Fully targeted mRNA therapeutics necessitate simultaneous organ-specific accumulation
and effective translation. Despite some progress, delivery systems are still unable to fully …

The messenger RNA (mRNA) vaccines hold great significance in contagion prevention and
cancer immunotherapy. However, safely and effectively harnessing innate immunity to …

Biodegradable two-dimensional nanomaterials could be a significant breakthrough in the
field of oncology nanotheranostic agents, which are rapidly emerging as promising …

Realizing the immense clinical potential of mRNA-based drugs will require continued
development of methods to safely deliver the bioactive agents with high efficiency and …

Lipid nanoparticles (LNPs) currently dominate the RNA delivery landscape; however their
limited diffusivity hampers targeted tissue dissemination, and, hence, their capacity for …

Cancer immunotherapy represents a promising targeted treatment by leveraging the
patient's immune system or adoptive transfer of active immune cells to selectively eliminate …

Abstract mRNA therapeutics utilizing lipid nanoparticle (LNP) delivery technology represent
a medical innovation for the treatment of various diseases. Amine-derived ionizable cationic …

RNA therapeutics, such as mRNA, siRNA, and CRISPR–Cas9, present exciting avenues for
treating diverse diseases. However, their potential is commonly hindered by vulnerability to …